About Salus Scientific
Salus Scientific makes radiation protection for doctors, nurses and technologists who work in fluoroscopy-guided procedures. Its products go after built-up scatter radiation exposure and the physical strain of heavy lead protection. The line includes GLiFT, AeroShield, Salus Garments and the Salus Lab service program.
Salus was founded in Charleston, South Carolina. Todd Flohr is co-founder, chief executive officer and chairman. Keith Rosmarin is president and chief financial officer, and Jon Wallace is general counsel. GLiFT is in use at U.S. health systems, and the company has opened two production facilities in South Carolina. It closed a $10.1 million Series A on August 5, 2026.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Not yet | Oct 22, 2026 | $0of $30.0M target | 0 | — | EquityRule 506(b) | Form D ↗ |
| Jan 22, 2026 | Feb 9, 2026amended Aug 5, 2026 | $10,120,000fully sold | 1 | $10.1M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Not yet | Oct 29, 2024 | $0of $2.0M target | 0 | — | Equity, OptionsRule 506(b) | Form D ↗ |
| Oct 27, 2022 | Nov 10, 2022 | $335,000of $2.0M target | 5 | $67,000 | EquityRule 506(b) | Form D ↗ |
| Total, four offerings | $10,455,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Rounds announced by Salus Scientific
What the company said publicly about its funding. Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.
| Announced | Round | Amount | Investors | Source |
|---|---|---|---|---|
| Aug 5, 2026 | Series A | $10.1 million | PR Newswire release ↗ |
Why Investors Backed Salus Scientific
Salus Scientific sells radiation protection to clinicians who work in fluoroscopy-guided procedures. The Charleston, South Carolina company closed a $10.1 million Series A in August 2026. Its GLiFT product is in use at U.S. health systems, and it has launched AeroShield. Salus's pitch is that one supplier can cover both radiation exposure and the strain of heavy lead.
The problem it targets
Doctors, nurses and technologists on interventional teams take in scatter radiation over a career. Traditional lead protection adds musculoskeletal strain and orthopedic injury. Salus points to more than 24 million fluoroscopy-guided procedures a year. A 2023 survey from the Society for Cardiovascular Angiography & Interventions, cited in a Salus release, found nearly 60 percent of interventionalists report orthopedic injuries tied to wearing lead protection.
What the product does
GLiFT is a patented endoskeleton that lifts the weight of lead off the body. AeroShield is a shielding system meant to cut scatter radiation exposure across the whole procedural team. Salus Lab covers garment management. The wider portfolio also spans dosimetry, education and radiation safety management. Salus's view is that these pieces together make the only full radiation protection solution for the lab.
Progress so far
Salus has launched AeroShield commercially. In August 2026 it published a clinical evaluation of AeroShield at Tallahassee Memorial Healthcare, written by William Dixon, M.D. A paper by W. Lance Lewis, M.D., covers apron weight redistribution with GLiFT. In summer 2026 Salus signed a distribution agreement with USVetServ to reach Veterans Affairs and Department of Defense facilities. It attends the TCT 2026 meeting in San Diego for the first time.
Who backs it
The Series A targeted $8.0 million. It closed at $10.1 million, above target and ahead of schedule. Flohr's view is that the oversubscribed round endorses the company's commercial thesis and execution. Keith Rosmarin, now president and chief financial officer, became the first non-founding investor in 2020, through his fund Harbor Hill Investments. He has since led the main financing rounds. William Gray, M.D., of Main Line Health, sits on the Salus Scientific Advisory Board.
How the market is moving
In 2026 several medical societies, led by SCAI, published an expert consensus statement on enhanced radiation protection. Its title is "Time for Mandatory and Urgent Action." In Salus's view, the statement has intensified the discussion of occupational radiation safety in procedural medicine. In June 2026 Salus applauded Arizona legislation on radiation safety in healthcare and urged other states to follow.
We wrote this summary from public statements by Salus Scientific and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on Salus Scientific's Form D filed Oct 22, 2026.
Earlier filings also listed Ryan Sancho (director, last listed Aug 2026).